Skip to content

Graduated Elastic compRession for vAricose Veins in PrEgnancy

Effect of Graduated Elastic compRession Hosiery on vAricose Veins and Leg Edema in PrEgnant Women

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05122195
Acronym
GRAPE
Enrollment
80
Registered
2021-11-16
Start date
2021-06-01
Completion date
2022-05-01
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Varicose Veins, Pregnancy Related, Quality of Life

Keywords

VV's, GSV, SSV, QoL

Brief summary

This study will be evaluate the clinical efficacy of using graduated compression hosiery for venospecific symptoms, leg edema, and quality of life (QoL) in pregnant women with varicose veins (VV's).

Detailed description

Each pregnant woman randomly receive an envelope. Those who received numbers 01 to 40 constitute the intervention group, and those with numbers 41 to 80 are in the control group.The intervention group will use a thigh length stockings with a compression of 23-32 mmHg, at least 8 hours a day. Verbal and written instructions on the proper use of the stockings will provide. During follow-up period, monitoring the regular use of compression stockings are performed every week. The physical characteristics of the patients, including the age, height, weight, and gestational week, are obtained and recorded. The clinical evaluation are performed using clinical-etiological and anatomical-pathophysiological assessment based on the CEAP classification. Clinical examinations, QoL assessment and duplex-ultrasound will perform two qualified physicians in the 160 lower limbs of the 80 pregnant women with VV's at three landmark periods: between the 12th and 15th (initial examination), 20th and 28th (intermediate examination), and between the 28th and 36rd (final examination) week of gestation. The study protocol includes examination of the deep and superficial venous system with recording the reflux time and great and small saphenous veins (GSV/SSV) diameters in seven preestablished points, 5 points in the GSV and 2 points in the SSV. A reflux time in the superficial veins above 0.5 s is considered pathological reflux. The ankle and lower leg circumference are measured using a measuring tape. Measurements are carried out at the lateral and medial ankle and the middle of the lower leg. All measurements are carried out at the same time of the respective days in the late afternoon or early evening; before the measurements the patients underwent a 45-min temperature and cardiovascular equilibrium period in a sitting position. The QoL and subjective symptoms: tired, heavy legs, sensation of tension, tingling, and pain are assessed at each visit before the volume measurements and ultrasonographic evaluation. The subjective symptoms are evaluated by use of a semiquantitative scale from 0 to 3: 0 = no symptoms; 1 = mild; 2 = moderate; and 3 = severe. The QoL is investigated at each visit by a Chronic Venous Insufficiency Questionnaire (CIVIQ).

Interventions

Graduated elastic compression promote venous flow which is impaired by hormonal changes in the venous system during the gestational period and minimize the blocking effect of the gravid uterus.

Sponsors

Belarusian State Medical University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

1. Pregnant women who are between the 12th and 15th weeks of gestation. 2. Primary symptomatic varicose veins, Clinical Etiological Anatomical Pathophysiological (CEAP) classification, clinical class C1-C3. 3. Ability to comprehend and sign an informed consent document.

Exclusion criteria

1. Deep venous thrombosis, thrombophilia associated with a high risk of deep venous thrombosis or postthrombotic syndrome. 2. Postoperative varicose vein disease recurrence. 3. History of pulmonary embolism. 4. Current compression therapy (within 7 days of enrollment). 5. CEAP clinical class C4-C6. 6. Arterial occlusive disease and lymphatic pathology of lower limbs. 7. Edema of limbs other than of venous origin.

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants with tired legs from absent (score 0) to severe (score 3)8 weeksNone (0), Occasional (1), Daily, intefering with, but not preventing daily activities (2), Daily, limiting most daily activities (3)
Responders to Treatment, Assessed by Duplex Ultrasound8 weeksResponders; Number of Participants with eliminated superficial pathological reflux between the 20th and 28th weeks of gestation
Number of Participants with reduction of the GSV and SSV diameters, Assessed by Duplex Ultrasound8 weeksResponders; reduction of the GSV and SSV diameters between the 20th and 28th weeks of gestation
Responders to Treatment, Assessed by a measuring tape8 weeksResponders; Number of Participants with reduction of the ankle and lower leg circumference between the 20th and 28th weeks of gestation
Number of Participants with pain from absent (score 0) to severe (score 3)8 weeksNone (0), Occasional (1), Daily, intefering with, but not preventing daily activities (2), Daily, limiting most daily activities (3)
Number of Participants with heavy legs from absent (score 0) to severe (score 3)8 weeksNone (0), Occasional (1), Daily, intefering with, but not preventing daily activities (2), Daily, limiting most daily activities (3)
Number of Participants with sensation of tension from absent (score 0) to severe (score 3)8 weeksNone (0), Occasional (1), Daily, intefering with, but not preventing daily activities (2), Daily, limiting most daily activities (3)
Number of Participants with tingling from absent (score 0) to severe (score 3)8 weeksNone (0), Occasional (1), Daily, intefering with, but not preventing daily activities (2), Daily, limiting most daily activities (3)

Countries

Belarus

Contacts

Primary ContactVladimir Khryshchanovich
vladimirkh77@mail.ru+375296245578
Backup ContactNicolay Rogovoy, MD
kolia_med@mail.ru+375293852753

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026